Skip to content

Cbio A/S, a developer of T-cell therapies, presents its 2023 annual report as part of preparations for clinical trials and announces the transition to the clinical phase with secured funding of DKK 40 million.

  • News

SØBORG, Dänemark, April 15, 2024 (GLOBE NEWSWIRE) — Cbio A/S – Pionier im Bereich T-Zell-Therapien der nächsten Generation für solide Tumore, gibt Finanzergebnisse für 2023 und aktuelle Unternehmensdaten bekannt. Cbio A/S, Entwickler von T-Zell-Therapien, stellt im Rahmen der Vorbereitungen zur klinischen Studie den Jahresbericht 2023 vor und kündigt mit einer gesicherten Finanzierung in Höhe von 40 Mio. DKK den Übergang zur klinischen Phase an

FDA Grants Soligenix Orphan Drug Designation Against Marburg Virus Infection

  • News

Soligenix announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for „the prevention and post-exposure prophylaxis against MARV infection.“ MarVax™ is a subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, developed in partnership with Dr. Axel Lehrer at the University of Hawai?i at M?noa. The vaccine includes a protein found on the surface of MARV, to engender an appropriate immune response without posing a risk of infection, as well as a novel adjuvant which stimulates both humoral and cell mediated immune responses, in combination with Generally Regarded as Safe (GRAS) excipients that enable lyophilization (i.e., freeze-drying) of the vaccine. The resulting product is manufactured as a… 

more »FDA Grants Soligenix Orphan Drug Designation Against Marburg Virus Infection

A quarter of deaths among young adults in Canada were opioid related in 2021

Premature deaths related to opioids doubled between 2019 and 2021 across Canada, with more than 1 in 4 deaths among young adults aged 20–39 years attributable to opioids, according to new research published in CMAJ (Canadian Medical Association Journal) Opioid-related deaths have continued to increase over the past decade across Canada, with 6222 deaths occurring in 2021. This trend worsened during the COVID-19 pandemic, although the scale and rapidity of increases varied across provinces and territories. These changes have been attributed primarily to the unregulated drug supply, which became increasingly volatile and unpredictable during the pandemic. JOURNALCanadian Medical Association Journal DOI10.1503/cmaj.231339

Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%

  • News

The Global Theranostics Market Size is to Grow from USD 1.9 Billion in 2023 to USD 3.3 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 5.68% during the projected period. Theranostics is a type of pharmaceutical treatment used in combination with diagnostics to maximize efficacy, safety, and expedite the discovery of new drugs. It is also known as integrated medicine, pharmacodiagnostics, companion diagnostics, and Dx/Rx partnership. It is the application of drugs in addition to diagnostic techniques. Theranostics is the process of combining medicinal treatment and diagnostics to expedite the creation of more affordable and effective medications. a quickly developing subject that the healthcare industry and regulatory organizations find intriguing. A number of factors are driving the global theranostics market, including the rising incidence of cancer globally and the resulting need for more specialized and potent therapies.… 

more »Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%

Global Deepfake AI Market Size To Exceed USD 119.34 Billion By 2033

The Global Deepfake AI Market Size was Valued at USD 6.83 Billion in 2023 and the Worldwide Deepfake AI Market Size is Expected to Reach USD 119.34 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Deepfake AI, or deep learning-based fake artificial intelligence, is the use of strong machine learning algorithms, particularly deep neural networks, to create or alter content that looks to be real but is actually artificial or fabricated. The term deepfake is derived from the combination of deep learning and fake. Deepfake AI technology is frequently used to make realistic-looking pictures, movies, or audio recordings using neural networks to mimic human behavior.

KI versagt in der Medizin

  • News

In einem Artikel in der Zeitschrift JAMA Pediatrics wurde festgestellt, dass der generative KI-Chatbot ChatGPT von OpenAI, den einige Gesundheitsorganisationen für begrenzte Anwendungsfälle getestet haben, bei der Diagnose pädiatrischer Krankheiten in 83 % der Fälle Fehler macht . Und beim Testen von OpenAIs GPT-4 als Diagnoseassistent stellten Ärzte am Beth Israel Deaconess Medical Center in Boston fest, dass das Modell in fast zwei von drei Fällen die falsche Diagnose als wichtigste Antwort einstufte. Die heutige generative KI hat auch mit medizinischen Verwaltungsaufgaben zu kämpfen, die fester Bestandteil der täglichen Arbeitsabläufe von Ärzten sind. Beim MedAlign-Benchmark zur Bewertung, wie gut generative KI Dinge wie das Zusammenfassen von Patientenakten und das Durchsuchen von Notizen leisten kann, scheiterte GPT-4 in 35 % der Fälle . OpenAI und viele andere Anbieter generativer KI warnen davor, sich bei medizinischer Beratung auf ihre Modelle zu verlassen… 

more »KI versagt in der Medizin

Advances in brain organoids from the lab

An artificial brain from the lab may sound like pure science fiction, but a Japanese-French research team has now actually developed a technique to connect lab-grown brain-like tissues. In a study in the journal Nature Communications, they compare their structure to the neural circuits in the human brain. Lab cultivation of brain cells The researchers at the Institute of Industrial Science […] Advances in brain organoids from the lab

aelf führt die Fusion von KI und Blockchain an, um die Zukunft der Technologie zu gestalten

  • News

Singapur (ots/PRNewswire) – Das in Singapur ansässige Blockchain-Unternehmen setzt auf künstliche Intelligenz, um neue Grenzen bei der Effizienz, Skalierbarkeit, Intelligenz und Sicherheit von Blockchain zu erschließen, und richtet einen 50-Millionen-Dollar-Ökosystemfonds zur Unterstützung der KI-Transformationsinitiativen ein. In einem für die Blockchain-Branche transformativen Schritt hat aelf, ein bahnbrechendes Blockchain-Netzwerk, seinen strategischen Wechsel zur Integration von künstlicher Intelligenz […] aelf führt die Fusion von KI und Blockchain an, um die Zukunft der Technologie zu gestalten

Pionierarbeit bei Spitzentechnologien: VITAL HealthCare, Entwickler hochwertiger medizinischer Bildgebungssysteme, präsentiert sich erstmals auf dem CMEF

Shanghai (ots/PRNewswire) – Am 11. April 2024 feierte VITAL HealthCare, einer der fünf Kerngeschäftsbereiche der VITAL-Gruppe, ein beeindruckendes Debüt auf der 89. China International Medical Equipment Fair (CMEF) in Shanghai. Gestützt auf die Kernkompetenz der Gruppe im Bereich Forschung und Entwicklung sowie auf die Fülle an hochwertigen Rohstoffen, Geräten, Modulen und System-F&E-Ressourcen hat sich VITAL […] Pionierarbeit bei Spitzentechnologien: VITAL HealthCare, Entwickler hochwertiger medizinischer Bildgebungssysteme, präsentiert sich erstmals auf dem CMEF

Biomerica Reports Third Quarter 2024 Financial Results

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2024 ended February 29, 2024. Biomerica Reports Third Quarter 2024 Financial Results